Table 3.

Complement targeting drugs used in transplant-associated thrombotic microangiopathy (TA-TMA) or potentially useful.

Drug	Type	Mechanism of Action	Mode of Administration	Response Rate	References
	Used in TA-TMA
Eculizumab	mAb	Inhibition of C5 and C5b9 formation	intravenous	Children 67–78%Adults 33–60%	[25,50,51,52,53,54,55,56,57,58,59]
Ravulizumab	mAb	Inhibition of C5 and C5b9 formation	intravenous	Under evaluation	NCT04543591
Coversin	Small protein	Inhibition of C5 and C5b9 formation	subcutaneous	Single case	[74]
Narsoplimab	mAb	MASP-2 inhibition	intravenous	Adults 61%	[79] NCT02222545
Pegcetacoplan	Peptide	C3 inhibition	subcutaneous	Under evaluation	NCT05148299
	Never used in TA-TMA
Crovalimab	mAb	Inhibition of C5 and C5b9 formation	subcutaneous
Iptacopam	Small molecule	Factor B inhibition	oral
Danicopan	Small molecule	Factor D inhibition	oral
BCX9930	Small molecule	Factor D inhibition	oral
Avacopan	Small molecule	C5a inhibition	oral
AMY-101	Peptide	C3 inhibition	subcutaneous